These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11199948)

  • 1. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study.
    Zanardi R; Artigas F; Moresco R; Colombo C; Messa C; Gobbo C; Smeraldi E; Fazio F
    J Clin Psychopharmacol; 2001 Feb; 21(1):53-8. PubMed ID: 11199948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study.
    Messa C; Colombo C; Moresco RM; Gobbo C; Galli L; Lucignani G; Gilardi MC; Rizzo G; Smeraldi E; Zanardi R; Artigas F; Fazio F
    Psychopharmacology (Berl); 2003 Apr; 167(1):72-8. PubMed ID: 12632246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.
    Meyer JH; Kapur S; Eisfeld B; Brown GM; Houle S; DaSilva J; Wilson AA; Rafi-Tari S; Mayberg HS; Kennedy SH
    Am J Psychiatry; 2001 Jan; 158(1):78-85. PubMed ID: 11136637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET.
    Meyer JH; Cho R; Kennedy S; Kapur S
    Psychopharmacology (Berl); 1999 Jun; 144(3):279-81. PubMed ID: 10435395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.
    Brody AL; Saxena S; Silverman DH; Alborzian S; Fairbanks LA; Phelps ME; Huang SC; Wu HM; Maidment K; Baxter LR
    Psychiatry Res; 1999 Oct; 91(3):127-39. PubMed ID: 10641577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.
    Moresco RM; Colombo C; Fazio F; Bonfanti A; Lucignani G; Messa C; Gobbo C; Galli L; Del Sole A; Lucca A; Smeraldi E
    Neuroimage; 2000 Oct; 12(4):452-65. PubMed ID: 10988039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study.
    Moresco FM; Dieci M; Vita A; Messa C; Gobbo C; Galli L; Rizzo G; Panzacchi A; De Peri L; Invernizzi G; Fazio F
    Neuroimage; 2002 Nov; 17(3):1470-8. PubMed ID: 12414286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.
    Goyer PF; Berridge MS; Morris ED; Semple WE; Compton-Toth BA; Schulz SC; Wong DF; Miraldi F; Meltzer HY
    J Nucl Med; 1996 Jul; 37(7):1122-7. PubMed ID: 8965181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
    Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF
    Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
    Meyer JH; Wilson AA; Ginovart N; Goulding V; Hussey D; Hood K; Houle S
    Am J Psychiatry; 2001 Nov; 158(11):1843-9. PubMed ID: 11691690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding.
    Perlmutter JS; Moerlein SM; Hwang DR; Todd RD
    J Neurosci; 1991 May; 11(5):1381-9. PubMed ID: 1827499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans.
    Barrio JR; Satyamurthy N; Huang SC; Keen RE; Nissenson CH; Hoffman JM; Ackermann RF; Bahn MM; Mazziotta JC; Phelps ME
    J Cereb Blood Flow Metab; 1989 Dec; 9(6):830-9. PubMed ID: 2531146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.
    Goldapple K; Segal Z; Garson C; Lau M; Bieling P; Kennedy S; Mayberg H
    Arch Gen Psychiatry; 2004 Jan; 61(1):34-41. PubMed ID: 14706942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects.
    Wang GJ; Volkow ND; Logan J; Fowler JS; Schlyer D; MacGregor RR; Hitzemann RJ; Gur RC; Wolf AP
    Life Sci; 1995; 56(14):PL249-53. PubMed ID: 7475891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone.
    Blin J; Sette G; Fiorelli M; Bletry O; Elghozi JL; Crouzel C; Baron JC
    J Neurochem; 1990 May; 54(5):1744-54. PubMed ID: 2182776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain.
    Coenen HH; Wienhard K; Stöcklin G; Laufer P; Hebold I; Pawlik G; Heiss WD
    Eur J Nucl Med; 1988; 14(2):80-7. PubMed ID: 2968911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression.
    Kennedy SH; Evans KR; Krüger S; Mayberg HS; Meyer JH; McCann S; Arifuzzman AI; Houle S; Vaccarino FJ
    Am J Psychiatry; 2001 Jun; 158(6):899-905. PubMed ID: 11384897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning.
    Swart JA; van der Werf JF; Wiegman T; Paans AM; Vaalburg W; Korf J
    J Cereb Blood Flow Metab; 1990 May; 10(3):297-306. PubMed ID: 1970341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.